Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Invesco Biotechnology & Genome ETF (NY:PBE)

78.96 +2.11 (+2.75%)

Streaming Delayed Price Updated: 1:09 PM EDT, Mar 31, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,118
Open	77.58
Bid (Size)	78.90 (700)
Ask (Size)	79.12 (500)
Prev. Close	76.85
Today's Range	77.58 - 78.96
52wk Range	54.52 - 85.73
Shares Outstanding	34,500
Dividend Yield	2.13%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗

January 26, 2026

The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.

Via Stocktwits

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗

November 05, 2025

Via Stocktwits

Performance

YTD	-4.1%	-4.1%
1 Month	-2.9%	-2.9%
3 Month	-5.4%	-5.4%
6 Month	+14.2%	+14.2%
1 Year	+24.5%	+24.5%

More News

Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion ↗

October 29, 2025

Via Stocktwits

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

Via Benzinga

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease ↗

September 23, 2025

Via Stocktwits

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential ↗

February 19, 2024

Via InvestorPlace

Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗

April 13, 2023

Via Benzinga

Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗

April 13, 2023

Via Benzinga

New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗

April 12, 2023

Via Benzinga

Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗

April 11, 2023

Via Benzinga

FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗

April 06, 2023

Via Benzinga

US Judge Weighs Nationwide Ban On Abortion Pills ↗

March 16, 2023

Via Benzinga

FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗

March 01, 2023

Via Benzinga

7 Best Biotech Stocks to Buy in July 2022 ↗

July 08, 2022

Via InvestorPlace

Biotech ETFs That Outperformed Last Week ↗

December 20, 2021

Via Talk Markets

A Comprehensive Guide To Genomic ETFs ↗

July 11, 2021

Via Talk Markets

5 Top ETFs With Exposure To Biogen ↗

June 07, 2021

Via Talk Markets

5 Top ETFs With Exposure To Biogen ↗

June 07, 2021

Via Benzinga

3 Biotech Stocks Wall Street Predicts Will Rally By 45% Or More ↗

May 30, 2021

Via Talk Markets

Frequently Asked Questions

Is Invesco Biotechnology & Genome ETF publicly traded?

Yes, Invesco Biotechnology & Genome ETF is publicly traded.

What exchange does Invesco Biotechnology & Genome ETF trade on?

Invesco Biotechnology & Genome ETF trades on the New York Stock Exchange

What is the ticker symbol for Invesco Biotechnology & Genome ETF?

The ticker symbol for Invesco Biotechnology & Genome ETF is PBE on the New York Stock Exchange

What is the current price of Invesco Biotechnology & Genome ETF?

The current price of Invesco Biotechnology & Genome ETF is 78.96

When was Invesco Biotechnology & Genome ETF last traded?

The last trade of Invesco Biotechnology & Genome ETF was at 03/31/26 01:09 PM ET

What is the market capitalization of Invesco Biotechnology & Genome ETF?

The market capitalization of Invesco Biotechnology & Genome ETF is 2.72M

How many shares of Invesco Biotechnology & Genome ETF are outstanding?

Invesco Biotechnology & Genome ETF has 3M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433